Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease
Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…A Phase 3 Study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update
Objective: To evaluate the efficacy of isradipine 10 mg daily to slow progression of disability in early PD. Background: Isradipine, a dihydropyridine calcium channel antagonist,…Differences in cerebral perfusion between Major depression disorder and depression with Parkinson’s disease : Brain HMPAO SPECT study using SPM analysis
Objective: We performed SPECT in Major depressive (MD) disorder and PD patients with (PDMD) and without depression (PDNMD). The aim of this work was to…Clinical Utility of Optimized Parameters for a Quantitative Analysis of 123I-ioflupane SPECT (DaTscan) Images
Objective: Validate an automated analysis of DaTscan SPECT images on a representative cohort of patients for discriminating between Parkinson's Disease (PD) versus non-PD. Background: Quantitation…Cortical phase-amplitude coupling across Parkinson’s disease phenotypes measured with magnetoencephalograph
Objective: To investigate how onset mode in Parkinson’s disease relates to cortical phase-amplitude coupling, a putative electrophysiological marker of pathological hypersynchronization. Background: Cortical circuitry in…Diffusion tensor imaging changes in the corpus callosum and cognitive impairment in Parkinson’s disease
Objective: To evaluate diffusion characteristics of the corpus callosum in Parkinson’s disease (PD) patients with varying degrees of cognitive impairment using Diffusion Tensor Imaging (DTI).…Non-motor symptoms in Parkinson’s disease and putamen dopamine transporter uptake (DaTscan) uptake: a survey of 85 patients
Objective: We addressed association between 30 non-motor symptoms (NMS) (using the validated Parkinson’s disease (PD) NMS Scale (NMSS)), and DaTscan putamen uptake ratios as part…The influence of LRRK2 mutations on cholinergic system in manifest and prodromal stage of Parkinson’s disease: a positron emission tomography study
Objective: To evaluate the effects of leucine-rich repeat kinase 2 (LRRK2) mutations on the central cholinergic system in both manifesting and non-manifesting carriers using PET…Modulation of executive motor network after neurofeedback training in Parkinson’s disease
Objective: To identify changes in effective (i.e. directed) connectivity in the executive motor network during finger tapping. To compare the effects of two rehabilitation strategies. …Volume analysis and localization of midbrain hyperechogenecities via TCS and MRI
Objective: We are presenting follow-up results on our previous study for 3D volumetric measurements of SN hyper-echogenicities, to differentiate PD patients from healthy controls (HC).…
- « Previous Page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- …
- 155
- Next Page »